arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

NOVAVAX INC

NVAX
$9.77 ▼ -0.88 (-8.26%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
66
Health
Good
Bullish
auto_awesome

Analytical Summary

NOVAVAX INC shows strong fundamentals with top-quartile Profit Margin (%) and Operating Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $1.6B
Dividend Yield —
Revenue Growth -76.3% ↗
Op. Margin -96.8% ↘
ROIC -56.3% ↘
FCF / Share $-0.44 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -1.53
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$56.70M
↓ -76.3% —
Net Income Profit after all expenses
$-53.39M
↓ -462.5% —
Operating Margin Operating profit as % of sales
-96.8%
↓ -775.6% 94th
FCF / Share Free cash flow per share
$-0.44
↓ -122.8% —
Long-Term Debt Long-term obligations
$291.49M
— +0.2% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
66
Financial Health
92
Cash Quality ↓
13

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters